Stock comparison
Haemonetics
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 77B | LMAT |
| Benjamin Graham | 85A | 89A | LMAT |
| Philip Fisher | 60C | 81C | LMAT |
| Peter Lynch | 54C | 67B | LMAT |
| Joel Greenblatt | 31F | 56D | LMAT |
| Charlie Munger | 54D | 68D | LMAT |
| Terry Smith | 55D | 69D | LMAT |
Side-by-side metrics
| Metric | HAE | LMAT |
|---|---|---|
| Market cap | $2.98B | $2.23B |
| P/E (TTM) | 24.8x | 37.1x |
| EV/EBIT | 14.1x | 36.6x |
| ROIC (TTM) | 8.37% | 9.43% |
| Gross margin | 55.74% | 72.39% |
| Net margin | 7.29% | 24.35% |
| Revenue CAGR 5y | 7.65% | 12.75% |
| EPS CAGR 5y | 24.62% | 19.04% |
| Debt / Equity | 1.5x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 36.6x+61%
- P/E (TTM)24.8xvs 37.1x+33%
- Market cap$2.98Bvs $2.23B+25%
- EPS CAGR 5y24.62%vs 19.04%+23%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 7.29%+70%
- Debt / Equity0.5xvs 1.5x+70%
- Revenue CAGR 5y12.75%vs 7.65%+40%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.